AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET 

Register for the event here

OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, April 16, 2026, at 4:00 PM ET. 

Mr. Equels will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.  

A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.  

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]

You May Also Be Interested In

• Join the Fun to Win a $2,000 Vehicle Purchase Voucher and Amazon Gift Cards | KAIYI Auto Invites You to Celebrate the World’s Biggest Football Summer
• Skyworks Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Qorvo’s Senior Notes due 2029 and 2031
• Unilumin at WOO 2026 London: Engineering a Smarter, More Sustainable Future for Global DOOH